A study looking at eribulin for advanced breast cancer

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Breast cancer

Status:

Closed

Phase:

Phase 4

This study is to find out more about the chemotherapy drug eribulin as a treatment for breast cancer that has spread into the surrounding tissue (locally advanced) or to another part of the body (secondary breast cancer). 

Doctors can treat locally advanced and secondary breast cancer with chemotherapy. One chemotherapy drug they use is eribulin. We know eribulin works, but not how well it works in practice.

In this study the researchers want to collect information about a group of people who are taking eribulin for their locally advanced or secondary breast cancer. This will include information about how you are doing, what other medications you are taking, any side effects and other treatments you may have.  

The aims of this study are to find out

  • How well eribulin works for people with locally advanced and secondary breast cancer
  • How safe it is

Who can enter

You may be able to enter this trial if

  • You are  taking eribulin at the moment
  • You have breast cancer that has spread to surrounding tissue (locally advanced) or has spread to another part of your body (secondary breast cancer)
  • Your cancer came back after treatment with 1 or 2 different types of chemotherapy
  • Your blood test results are satisfactory
  • You are at least 18 years old

You cannot enter this trial if

  • This isn’t the first time you have taken eribulin
  • You have had treatment for locally advanced or secondary breast cancer with more than 2 different types of chemotherapy

 

Trial design

This is a phase 4 study. It will recruit 150 people. Everyone will have eribulin.

While you are on the study, your cancer doctor will collect information about how you are doing, what other medications you are taking, any side effects and other treatments you may have as long as you are taking eribulin.   

You remain part of the study as long as you are taking eribulin.

Hospital visits

There are no extra visits to the hospital if you take part in this study.

Side effects

We have information about eribulin and its side effects in our cancer drugs section.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Hartmut Kristeleit

Supported by

Eisai
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10960

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Harriet wanted to try new treatments

A picture of Harriet

“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page